Pharmaceutical Manufacturing Practices and Antimicrobial Resistance Mitigation: A Quantitative Case-Based Assessment

Abstract

Antimicrobial resistance (AMR) remains one of the most pressing threats to global public health, yet scholarly and policy attention has largely concentrated on clinical prescribing behavior and patient-level misuse, leaving the upstream contribution of pharmaceutical manufacturing comparatively underexamined. This study addresses that gap by investigating how deficiencies in production discipline, quality control, waste handling, and compliance infrastructure may elevate resistance-related risks through the circulation of substandard antimicrobial products and the unsafe discharge of pharmaceutical effluents into the environment. Accordingly, the study evaluates the effects of four manufacturing dimensions, Good Manufacturing Practice (GMP), Quality Control Systems, Waste Management and Environmental Safety, and Regulatory Compliance, on Antimicrobial Resistance Mitigation across selected pharmaceutical enterprise case settings. A quantitative, cross-sectional, case-based design was adopted, with primary data collected through structured questionnaires administered to personnel drawn from production, quality assurance, quality control, regulatory compliance, and environmental health and safety functions across four manufacturing sites. Of 230 instruments distributed, 214 valid responses were retained, yielding a response rate of 93.0%. The data were analyzed using descriptive statistics, Pearson correlation, and multiple regression analysis.Descriptive findings revealed uniformly high ratings across the study constructs: GMP (M = 4.18, SD = 0.64), Quality Control Systems (M = 4.11, SD = 0.69), Regulatory Compliance (M = 4.06, SD = 0.67), Waste Management and Environmental Safety (M = 3.97, SD = 0.73), and Antimicrobial Resistance Mitigation (M = 4.14, SD = 0.61). Correlation analysis indicated that GMP exhibited the strongest association with mitigation outcomes (r = .68, p < .001), followed by Regulatory Compliance (r = .66), Quality Control Systems (r = .63), and Waste Management and Environmental Safety (r = .59). Regression results corroborated these relationships, identifying GMP as the strongest predictor (β = .31, p < .001), followed by Regulatory Compliance (β = .27, p < .001), Quality Control Systems (β = .24, p = .002), and Waste Management and Environmental Safety (β = .19, p = .008). Collectively, the four predictors accounted for 47.3% of the variance in mitigation outcomes (R² = .473; F = 46.82, p < .001).The findings underscore that pharmaceutical manufacturing should be conceptualized not merely as an industrial activity but as a critical public health control system, one that plays a decisive role in preserving antimicrobial efficacy and curbing the emergence and spread of resistance.